Allos CEO resigns
Executive Summary
Allos Therapeutics CEO and CFO Michael Hart will resign his positions following appointment of a successor CEO. During Hart's tenure, Allos received an "approvable" letter for Efaproxyn (efaproxiral) for use as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer (1"The Pink Sheet" June 7, 2004, p. 6). Hart joined Allos in 1999 as chief financial officer and senior VP-operations. He was promoted to president and CEO in December 2001, and appointed to the board of directors in April 2002...
You may also be interested in...
Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Approval of Allos' oncologic efaproxiral will need to await positive data from an ongoing Phase III study in patients with brain metastases originating from breast cancer, an FDA "approvable" letter states
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.